These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 678161)

  • 41. [Echocardiography during exercise and coronary disease].
    Fedele F; Agati L; Penco M; Arata L; Pastore LR; Giannico S
    Boll Soc Ital Cardiol; 1979; 24(8):817-32. PubMed ID: 551806
    [No Abstract]   [Full Text] [Related]  

  • 42. [Verapamil in a single dose, evaluation by means of the ergometric test].
    Pereira MH; Brito FS; Pereira CB; Lion MF
    Arq Bras Cardiol; 1977 Feb; 30 Suppl 1():83-94. PubMed ID: 889475
    [No Abstract]   [Full Text] [Related]  

  • 43. [Cycloergometric evaluation of the continuous use of verapamil 360 mg/per day in chronic coronary insufficiency].
    Figueira RH; Bozza AE; Guimarães F; Terra LS; Silva O; Pereira E; Maiolino E; Dohmann HJ
    Arq Bras Cardiol; 1977 Feb; 30 Suppl 1():55-8. PubMed ID: 329808
    [No Abstract]   [Full Text] [Related]  

  • 44. [The antiarrhythmic and coronary-dilating properties of verapamil in patients ith ischemic heart disease].
    Votcal BE; Lozinskij LG; Goldberg VA; Venediktova MG; Gribova OA
    Arzneimittelforschung; 1970 Sep; 20():Suppl 9a:1281+. PubMed ID: 5312386
    [No Abstract]   [Full Text] [Related]  

  • 45. Effects of ouabain on myocardial oxygen supply and demand in patients with chronic coronary artery disease. A hemodynamic, volumetric, and metabolic study in patients without heart failure.
    DeMots H; Rahimtoola SH; Kremkau EL; Bennett W; Mahler D
    J Clin Invest; 1976 Aug; 58(2):312-9. PubMed ID: 783197
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Hemodynamic effects of a new inhibitor of adrenergic beta receptors (LB 46)].
    Lejwi G; Fabiato A; Gut JP; Gourgon R
    Arch Mal Coeur Vaiss; 1971 Nov; 64(11):1654-68. PubMed ID: 4402388
    [No Abstract]   [Full Text] [Related]  

  • 47. Intravenous verapamil blunts hyperdynamic responses during electroconvulsive therapy without altering seizure activity.
    Wajima Z; Yoshikawa T; Ogura A; Imanaga K; Shiga T; Inoue T; Ogawa R
    Anesth Analg; 2002 Aug; 95(2):400-2, table of contents. PubMed ID: 12145060
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Effect of verapamil on the cycloergometric test in patients with coronary artery disease (complementary study)].
    Martins de Oliveira J
    Arq Bras Cardiol; 1979 Feb; 32(2):135-7. PubMed ID: 464855
    [No Abstract]   [Full Text] [Related]  

  • 49. [Effect of verapamil in supraventricular extrasystole. Evaluation by dynamic electrocardiography (Holter system)].
    Rocha PJ; Albanesi FM; Albuquerque DC; Benchimol CB; Schlesinger P; Benchimol AB
    Arq Bras Cardiol; 1979 May; 32(5):347-51. PubMed ID: 92982
    [No Abstract]   [Full Text] [Related]  

  • 50. Influence of severity of ventricular dysfunction on hemodynamic responses to intravenously administered verapamil in ischemic heart disease.
    Chew CY; Hecht HS; Collett JT; McAllister RG; Singh BN
    Am J Cardiol; 1981 Apr; 47(4):917-22. PubMed ID: 7211708
    [No Abstract]   [Full Text] [Related]  

  • 51. Hemodynamic effects of high dosages of verapamil and the lack of protection by 4-aminopyridine in the rabbit.
    Wesseling H; Houwertjes MC; de Langen CD; Kingma JH
    Arch Int Pharmacodyn Ther; 1983 Nov; 266(1):106-12. PubMed ID: 6667060
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A new type of contrast medium in selective coronary arteriography.
    Björk L; Erikson U; Ingelman B
    Ups J Med Sci; 1972; 77(1):19-21. PubMed ID: 5052771
    [No Abstract]   [Full Text] [Related]  

  • 53. [Hemodynamic effect of a single intravenous dose of verapamil in patients with hypoxemic pulmonary hypertension].
    Poloński L; Tendera M; Wodniecki J; Pudelski J; Polońska A; Kardaszewicz P
    Pneumonol Pol; 1988 Sep; 56(9):398-405. PubMed ID: 3254514
    [No Abstract]   [Full Text] [Related]  

  • 54. The beneficial effects of cyclovirobuxine D (CVBD) in coronary heart disease. A double blind analysis of 110 cases.
    Shan P; Mao RB; Xu JM; Li JX
    J Tradit Chin Med; 1984 Mar; 4(1):15-9. PubMed ID: 6381892
    [No Abstract]   [Full Text] [Related]  

  • 55. [Clinical and hemodynamic effect of piracetam (Nootropil) in elderly and very old patients with coronary heart disease in the outpatient rehabilitative period].
    Pimenov LT; Kalinina SA; Churshin AD
    Kardiologiia; 1992 May; 32(5):35-7. PubMed ID: 1405257
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Once-daily verapamil.
    Dunn JM; Groth PE
    Lancet; 1984 Dec; 2(8415):1338-9. PubMed ID: 6150346
    [No Abstract]   [Full Text] [Related]  

  • 57. [Clinico-experimental basis of prolonged-action retrosternal block in coronary insufficiency].
    Fornel' MB
    Kardiologiia; 1966; 6(1):69-72. PubMed ID: 5970410
    [No Abstract]   [Full Text] [Related]  

  • 58. [Hemodynamic effects of verapamil in patients with coronary insufficiency].
    Lamounier EN; Martinez EE; Herrmann JL; Guimarães RF; Martinez TL; Portugal OP
    Arq Bras Cardiol; 1978 Feb; 31 Suppl 1():11-14. PubMed ID: 678161
    [No Abstract]   [Full Text] [Related]  

  • 59. [Hemodynamic evaluation of the action of calcium antagonists].
    Vincenzi M; Allegri P; Barbieri E; Cappelletti F; Carrozza A; De Lio U; Maiolino P; Morlino T; Ometto R
    Boll Soc Ital Cardiol; 1978; (1 Suppl):79-97. PubMed ID: 757682
    [No Abstract]   [Full Text] [Related]  

  • 60. [The effect of verapamil in coronary insufficiency and cardiac arrhythmia].
    Bobkova VI; Solomonova LN; Majorov JM; Karpickij VS; Mazurova SV
    Arzneimittelforschung; 1970 Sep; 20():Suppl 9a:1285+. PubMed ID: 4098327
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.